<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129775</url>
  </required_header>
  <id_info>
    <org_study_id>413-201901</org_study_id>
    <nct_id>NCT04129775</nct_id>
  </id_info>
  <brief_title>OTO-413 in Subjects With Speech-in-Noise Hearing Impairment</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otonomy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otonomy, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy
      of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise
      hearing impairment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events (Safety)</measure>
    <time_frame>Reported or observed during or after dosing (Day 1) up to the end of study (Day 85 - 12 weeks after dosing)</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended diagnosis, symptom, sign, syndrome or disease which occurs during the study, having been absent at baseline, or if present at baseline, appears to worsen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Otoscopic Examinations (Safety)</measure>
    <time_frame>After dosing (Day 1) up to end of study (Day 85 - 12 weeks after dosing)</time_frame>
    <description>Clinically significant change form Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Audiometry (Safety)</measure>
    <time_frame>After dosing (Day 1) up to end of study (Day 85 - 12 weeks after dosing)</time_frame>
    <description>Clinically significant change from Baseline</description>
  </primary_outcome>
  <other_outcome>
    <measure>Speech-in-noise Hearing Tests</measure>
    <time_frame>At 2 weeks, 4 weeks, 8 weeks and 12 weeks after dosing</time_frame>
    <description>Ability to hear over noise</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrophysiological Endpoint</measure>
    <time_frame>At 4 weeks, 8 weeks and 12 weeks after dosing</time_frame>
    <description>Electrophysiological test of auditory brainstem response to auditory stimuli</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>At 4 weeks, 8 weeks and 12 weeks after dosing</time_frame>
    <description>Change in overall hearing status, ranging from very much worse (-3) to very much improved (+3)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sensorineural Hearing Loss</condition>
  <arm_group>
    <arm_group_label>OTO-413</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTO-413</intervention_name>
    <description>Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)</description>
    <arm_group_label>OTO-413</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single intratympanic injection of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has audiometrically-defined normal hearing or mild hearing impairment.

          -  Subject has self-reported difficulty hearing in noisy environments for at least 6
             months prior to Screening.

          -  Subject exhibited a speech-in-noise hearing deficit in at least one ear.

        Exclusion Criteria:

          -  Subject is pregnant or lactating.

          -  Subject has the following hearing disorders or any other hearing disorders that may
             impact the efficacy assessments or safety of the subject in the opinion of the
             Investigator: Meniere's disease, congenital hearing loss, or genetic sensorineural
             hearing loss.

          -  Subject has a cochlear implant or consistently uses a hearing aid.

          -  Subject has worked at least 5 years as a professional musician or has had at least 15
             years of formal musical training.

          -  Subject self-reports bothersome, subjective tinnitus and is consistently aware of
             their tinnitus throughout much of the waking day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Florida ENT Associates or Research Centers of America</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter G Volsky, MD</last_name>
      <phone>954-990-7649</phone>
      <email>suri.mederos@rcatrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Surisaday Mederos</last_name>
      <phone>954-990-7649</phone>
      <email>suri.mederos@rcatrials.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Sanchez</last_name>
      <phone>813-974-1262</phone>
      <email>arctlab@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health Hearing &amp; Speech Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginny Mullooly</last_name>
      <phone>718-470-7974</phone>
      <email>gmullool@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Bertoch, MD</last_name>
      <phone>801-261-2000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hearing loss</keyword>
  <keyword>speech-in-noise</keyword>
  <keyword>synaptopathy</keyword>
  <keyword>hearing impairment</keyword>
  <keyword>hidden hearing loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

